Answers are grounded in this paper and cite their sources.
Background Dual-phenotype hepatocellular carcinoma (DPHCC) is a rare subtype of HCC that co-expresses hepatocellular and cholangiocellular immunohistochemical markers and exhibits high aggressiveness. Evidence regarding the prognosis of patients with postoperative recurrent DPHCC receiving interventional therapy combined with targeted therapy and immune checkpoint inhibitors (ICIs) remains scarce. Methods In this retrospective cohort study, 35 patients with postoperative recurrent HCC treated at Xiamen Hospital of Traditional Chinese Medicine between January 2019 and March 2026 were analyzed; all received interventional therapy (transarterial chemoembolization [TACE] or hepatic arterial infusion chemotherapy [HAIC]) combined with targeted therapy and ICIs. Patients were classified into a DPHCC group (n = 17) and a conventional HCC group (n = 18) according to pathological immunohistochemical findings. The primary endpoints were post-recurrence overall survival (OS) and progression-free survival (PFS). Survival curves were estimated using the Kaplan–Meier method and compared using the log-rank test. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox proportional hazards models. Restricted mean survival time (RMST) was calculated to complement median survival estimates. Results Post-recurrence OS was significantly shorter in the DPHCC group than in the conventional group (median, 18.2 vs. 36.8 months; HR, 2.75; 95% CI, 1.15–6.59; P = 0.019), and the RMST for OS at 12 months was correspondingly shorter in the DPHCC group. Post-recurrence PFS also tended to be shorter in the DPHCC group (median, 4.6 vs. 9.8 months; HR, 1.78; 95% CI, 0.86–3.68; P = 0.120). Conclusions Among patients with postoperative recurrent HCC treated with interventional therapy combined with targeted therapy and ICIs, the dual-phenotype subtype was associated with poorer post-recurrence survival. DPHCC may represent a high-risk subtype requiring closer surveillance and more aggressive systemic treatment strategies after postoperative recurrence.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: